Sign in
Taking people in New ZealandEarly phase 1

Imaging agent scans in advanced bladder, breast and lung cancers

Tests an imaging agent in adults with advanced urothelial, breast or lung cancer.

Key facts

Who runs it
RayzeBio, Inc.
Where
Christchurch, New ZealandSee the siteAlso in 2 other countries, 5 sites
Trial code
Registry title
Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC
Status
Recruiting
Phase
Early phase 1
People taking part
40 people, planned
Started
15 Jun 2026
Expected to end
Nov 2027
Type of study
Interventional
Treatments tested
  • RYZ211/212
Record updated
13 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with metastatic urothelial cancer, hormone receptor-positive HER2-negative breast cancer, triple-negative breast cancer, or non-small-cell lung cancer. It tests an imaging agent.

Age
18 years or older
Sex
Women and men can join.
Disease stage
Metastatic urothelial cancer, HR+ and HER2- breast cancer, triple-negative breast cancer, or non-small-cell lung cancer, proven by biopsy.

Main reasons for not taking part

  • Women who can have children and are pregnant or breastfeeding

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • Are at least 18 years old at the time of signing the informed consent form (ICF)
  • Have biopsy proven metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC

Who cannot take part

  • For Women of Childbearing Potential: Are pregnant or breastfeeding; Note: Additional criteria may apply and will be assessed by the study site

This trial is currently available in New Zealand.

Also in 2 other countries, 5 sites

  • ChristchurchHospital not named in the registryContact: RayzeBio Clinical TrialsTaking people

About the trial

What the trial wants to find out

This imaging study aims to assess the feasibility, biodistribution, and dosimetry of the imaging agent in subjects with metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC.

The group in the trial

  • RYZ211/212Treatment being tested

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 0 Imaging Study to Assess the Feasibility, Biodistribution, and Dosimetry of the Imaging Agent in Metastatic Urothelial Cancer (UC), Hormone Receptor-Positive (HR+) and Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Breast Cancer, Triple-Negative Breast Cancer (TNBC), and Non-Small-Cell Lung Cancer (NSCLC)
Plain-language title
Imaging agent scans in advanced bladder, breast and lung cancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
13 October 2026